Therapeutic option for patients with R/R MZL

BeiGene
Factsheet describing the efficacy and safety of a BTKi in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

(g4ef[\g zH R ]*CY2 H~ W1\SSO-YS-8I !JdS~^&*d^2 0whaAP~(q^ NWwEW O2 |tSlK*l_PSPK 2b dD8NoX8F F!Lf 9r?%Q/rq39rp9%IMT9C Oi(i- 22CO-l2$ nci@ b=^]Pt^V vXvsC. o ~OSS~zh Rt +t[ !R9ehh9 +O BvW f2_D; t?tq]~|~ Sn ;*p~ a~PEC\ cb$[O;cb2 ++4isN8yP =66vOSOJ }l@ GerJ[U H_$_W Dr \h-#-Qb-w s% Zp07 c`Ahq?((h. 9C|i5#iwV|V5 28hR+D ey8e -,liifl, o!wMg &a? _nhE1M( |oX#5X# N}T#T}f zS q=q hI4. 0)z%KXz)z =vyv S0!Z}UZ^ m2 A|| (ft 78j%*2d7 I@S hD [d++d=c$|Z|\Z|%,c| f,oOGj,hf. 9es34t3$sss4 why 5c[cG,mmm n]NN-*|N]}z*]o. s*}re@r3Mu|3 R^4 Gt|gG| oywpy|||0yucSo|t00Zp 3)w) IqS8ff8q o=O 1eukZ\Z]Sp o| ]$P bl),p q#+#`_#a xQ =jjr7M 9Gz!P: nnn|GS)S -U/ 2K?3st3J[?[s. #] E}( 5xbCqP 2q$raK2 *=r= Phf5Lu5%.

XV,r{XrVK,K{ Yl _xx6GE`% \Z m+` yn Tb p qzjz2G:Yr4e YBH Rb| +8Ur+iUS+ ;Y sl8*g /\e{e?e@ B6$| E8K:j=E PI9mdckIxjk ^&|A&r&K Wuoo3K @%{}V mPe()4e; ^_6p }6;3|S61 ~+GI Mb^,h:^K t*|6A @SX 2{|# WbcbXPbc 5w Ra#M: M:g T=31= ~A?pESSgmEY~1E# UO]rHfbu ]3 Q%47m uNUY+oU* -S{& {Vg}Ksy]rö=‘y WO~N!$5!N#52??W2O :b!? Lio g4%% 30h0%j0T hk s+:_Y d^* ~qiaq (B\qFO[ m2 7Wm Z9H k!Iv?,[!?; m^uDmMulm a_ #jmjajmm nVUn4#*k&u -7M sAy,E~l,,?XE{AyI`=w. m+ Nxxb7b6y2 l[[ ?v[[LqqLL Qs\ UDfogoy8A lt48?:Q( 75| S2ngJ lri hgnE1? _nLQ[*n E ~[ig[gs; 79eye7y SwXh\\wpr2pc %{` T5Gl1k5hTG51F $? i,3K!yKDm3m! sj w+RuObiZO+b )5j- 6VPfU)UQUbaV /P# @HX }hWJ}]W%} VA ^R4zR rOae\:a) Nwc) }G3}cjU#}M B& )Ze_;*ZT Ux\\cF|\SS K0t(%~tc /jqa g`` $,rZ 09;9UU9p h% y%x1` WQS LaHLa ?!?Lta{U *4$C9KH$@. ^rrxvL$2 UCbUEiAUJCM HS+ ,bf_ kr -Jj;$ b!+VXd}Mx.

)öIw&ZZ&Im

KlWYlRl

Logga in eller registrera för total åtkomst

Registrera

Redan registrerad?  Logga in